Searched for
DRREDDYS
Two Trades for Today: A pharmaceutical major for a 5.05% rise, a mid-cap defence stock for an almost 6% gainOur technical analysts identify select stocks that may gain momentum even in volatile markets. Here are the technical calls for today.- Dr. Reddy’s shares rise over 1% on strategic collaboration with Alvotech for Keytruda BiosimilarDr. Reddy’s Laboratories has partnered with global biotech firm Alvotech to co-develop and commercialize a biosimilar of Keytruda (pembroli...
- Buy Dr. Reddy's Laboratories, target price Rs 5600: Axis SecuritiesDr. Reddy's Laboratories Ltd., incorporated in the year 1984, is a Large Cap company (having a market cap of Rs 77528.53 Crore) operating i...
- India drug regulator asks Dr.Reddy's for more data on Sputnik V COVID-19 vaccineThe committee asked the company to submit a comparative analysis of late-stage immunogenicity data from both its Indian studies and an ongo...
- India's Dr.Reddy's ends study of COVID-19 drug Avigan in KuwaitData from the Kuwait trial, conducted in partnership with United Arab Emirates-based medical alliance Global Response Aid FZCO (GRA), showe...
- Experienced information security incident that affected select internal IT systems: LupinRestoration of the impacted systems is a priority and is underway, it added. The incident comes after another pharma major DrReddy's Labora...
- Dr Reddy's completes the acquisition of Wockhardt's select generics, plantG V Prasad, Co-Chairman and Managing Director of Dr. Reddys said this deal is in line with the companys strategic focus on India and has pa...
- Top quant strategies for the week aheadThis pair has 90% correlation over the last few weeks post its ex corporate action.
- Share market update: Glenmark Pharma, Dr.Reddy's Lab among top losers on BSEIn the Nifty pack, 32 stocks were trading in the green, while 17 stocks were in the red.
- USFDA issues 5 observations to Dr Reddy's plant in HyderabadDr.Reddy's Laboratories was issued a Form 483 which notifies the company's management of objectionable conditions, with 5 observations.
- Top quantitative strategies for the weekTata Motor has more probability to witness short covering bounce then Tata Motor DVR.
- Top Quant play strategies for the weekTata Motor has more probability to witness short covering bounce then DVR.
- Dr.Reddy's launches anti-cancer injection in US marketThe drug, which is used to treat certain types of cancer, was earlier approved by the US Food and Drug Administration (USFDA), DRL said in ...
- Top quant strategies for the weekThis pair has 97 per cent correlation over the last one year.
- Top quantitative strategies for the weekTop quantitative strategies for the week by Shubham Agarwal, Head of Quantitative Research, MOSL.
- South Korean drug firm sues Dr Reddy's for misrepresenting complianceThe suit states that Dr Reddy's repeatedly represented to Mezzion that it was compliant with FDA regulations, and that it hid its misconduc...
- Equal weight on DRL, but target cut to Rs 3,339: Morgan StanleyThe brokerage said near-term earnings challenge is underestimated while long-term prospects look intact.
- Buy Dr. Reddy with target price of Rs 2539: Sandeep WagleDr. Reddy is a ‘Buy’ with a target of Rs 2539 and a stop loss of Rs 2460.
- Buy Dr Reddy’s with a target of Rs 2385: Sandeep WagleDr Reddy’s is a 'BUY' call with a target of Rs 2385 and a stop loss of Rs 2290.
- DrReddy's Jan futures seen rising to Rs 514Religare Securities has recommended buying futures contracts of DrReddy's at Rs 481-484, as it expects the stock to touch Rs 514 in the nea...
Load More
